Valiant Laboratories
87.90
-0.14(-0.16%)
Market Cap₹477.41 Cr
PE Ratio-
IndustryHealthcare
Company Performance:
1D-0.16%
1M+1.35%
6M+12.74%
1Y-18.93%
5Y-48.37%
View Company Insightsright
Latest news about Valiant Laboratories
Valiant Laboratories Reports Robust Q1 Results, Approves Key Management Changes Aug 08, 2025
Valiant Laboratories reported a significant increase in Q1 financial performance, with revenue from operations growing 147.9% year-over-year to Rs. 4,682.27 crore. The company turned profitable with a net profit of Rs. 182.09 crore, compared to a loss in the previous year. The board approved the redesignation of Mr. Paresh Shah as Whole-time Director and Key Managerial Personnel for a five-year term. Additionally, M/s. Mehta & Mehta was appointed as the new Secretarial Auditor for a five-year term. Both appointments are subject to shareholder approval at the upcoming Annual General Meeting.
Valiant Laboratories Announces Rights Issue: ₹75 Per Share with 1:4 Entitlement Ratio Jul 15, 2025
Valiant Laboratories Reports Turnaround in Q4 with Improved EBITDA and Revenue May 20, 2025